|Bid||16.30 x 1200|
|Ask||16.91 x 1000|
|Day's range||15.65 - 16.74|
|52-week range||15.16 - 42.57|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||36.33|
Insiders who bought US$184k worth of Sight Sciences, Inc. ( NASDAQ:SGHT ) stock in the last year have seen some of...
In this segment of Backstage Pass, recorded on Dec. 13, 2021, Fool contributor Asit Sharma discusses a newly public healthcare stock that long-term investors may want to put on their radar right now. Asit Sharma: What is Sight Sciences (NASDAQ: SGHT)? This is a company founded in 2011 by two brothers, David and Paul Badawi.
Sight Sciences (NASDAQ: SGHT) only recently made its public debut. Since the company's initial public offering last summer, shares have plunged by nearly 50%. Is this company, which markets medical devices to treat diseases of the eye, one that investors should put on their watch list right now?